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DEVELOPMENT OF A MULTIATTRIBUTE INSTRUMENT FOR ESTIMATING
UTILITIES (PREFERENCE WEIGHTS) IN PEOPLE WITH GLAUCOMA FROM THE
NATIONAL EYE INSTITUTE VISUAL FUNCTIONING QUESTIONNAIRE (NEI-VFQ)
Kymes S1, Peters CM1, Beusterien K2, Kotak S3, Grinspan J2, Stwalley D4, Pleil A5
1Washington University School of Medicine, St. Louis, MO, USA, 2Oxford Outcomes Ltd.,
Bethesda, MD, USA, 3Pfizer, Inc., New York, NY, USA, 4Washington University, St. Louis, MO,
USA, 5Pfizer, Inc., San Diego, CA, USA
OBJECTIVES:We used multi-attribute theory to develop a utility elicitation instru-
ment for people with glaucoma based on the National Eye Institute-Visual Func-
tioning Questionnaire (NEI-VFQ), a vision specific quality of life instrument fre-
quently used in clinical trials. METHODS: NEI-VFQ responses for 1677 people
enrolled in glaucoma prevention trials were analyzed to identify items responsive
to differences in vision status. We then constructed a conjoint interview adminis-
tered to 48 people with glaucoma and identified the 6 items of greatest importance
to people with glaucoma. Using these results, we constructed a web-based inter-
view using standard gamble (SG) and visual analog scales(VAS) administered to a
community sample of 404 people. RESULTS: The five attributes most important to
people with glaucoma (and responsive to change in disease status) were: ability to
read, driving at night, ability to leave home, needing help with activities and ability
to accomplish tasks. We added a sixth attribute, peripheral vision, even though it
was not rated highly by the participants as this is an important function lost early
in the disease process. Final utility estimates weremade using amethod similar to
that employed in the Health Utility Index. The results had excellent face validity
and we note the range of utility loss frommild loss of function to severe difficulty:
1) Ability to read (0.011-0.039); 2) Driving at night (0.011-0.037); 3) Leaving home
(0.014-0.056); 4) Needing help with activities (0.027-0.063); 5) Ability to accomplish
tasks (0.016-0.046); and 6) Peripheral vision (0.008-0.032). CONCLUSIONS:We have
developed an instrument that can be used to estimate the utility loss in peoplewith
glaucomabasedupon theNEI-VFQ.Whenused in clinical trials, the instrumentwill
provide an estimate of the utility loss associatedwith the progression of glaucoma.
Further work will be required to refine and validate these estimates.
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DEVELOPMENT OF A DISEASE SPECIFIC VERSION OF THE EQ-5D FOR USE IN
PSORIASIS
Lloyd A1, Swinburn P1, Boye KS2, Edson E2, Bowman L2
1Oxford Outcomes Ltd., Oxford, Oxfordshire, UK, 2Eli Lilly and Company, Indianapolis, IN, USA
OBJECTIVES: The EQ-5D is a widely used generic measure of health. Previous re-
search has highlighted possible shortcomings in content validity in certain condi-
tions (e.g. vision, hearing loss). The objective of this study was to determine if this
was true for people with psoriasis and to address this through the development of
a disease-specific version of the EQ-5D for use in psoriasis.METHODS: A literature
review, consultationwithmedical experts and in-depth qualitative interviewswith
psoriasis patients with varying degrees of disease severity (n8) were undertaken
to understand the quality-of-life burden associated with psoriasis. An iterative
process identified four new candidate dimensions (skin irritation, skin appearance,
self-confidence and social/relationship difficulties). Thesewere included alongside
the existing five dimensions of EQ-5D. In a validation study 100 psoriasis patients
completed the new version of EQ-5D; the Dermatology Life Quality Index (DLQI)
and Self-Administered Psoriasis Area Severity Index (SAPASI). RESULTS: Psycho-
metric analyses suggested that all candidate dimensions were sensitive to disease
severity and had excellent concurrent validity. The new dimensions significantly
improved the predictive power of EQ-5D inmeasuring health status as assessed by
the DLQI with an R2 increase of 0.213 when three candidate dimensions were
added. Almost 20% of patients indicated no problems on each dimension of con-
ventional EQ-5D (state 11111), but reported substantial impairments on the psori-
asis dimensions, indicating the limitations of existing EQ-5D in psoriasis.
CONCLUSIONS: This study is part of larger research at the EuroQol Group to inves-
tigate the potential development of disease specific versions of EQ-5D. The study
demonstrates that in certain disease areas there is need for more a specific mea-
sure. The addition of appropriate dimensions can significantly increase the sensi-
tivity of the instrument. Further work is needed to capture preference weights for
this new instrument to support its inclusion in economic evaluation.
PSS17
THE EFFECT OF ORAL CP-690,550 ON PRURITUS IN PATIENTS WITH
MODERATE-TO-SEVERE PLAQUE PSORIASIS
Mamolo CM1, Bushmakin AG2, Cappelleri JC2, Stewart M2
1Pfizer, Inc., New London, CT, USA, 2Pfizer Global Research and Development, Groton, CT, USA
OBJECTIVES: To assess the effect of the oral Janus kinase inhibitor CP-690,550 on
pruritus in patientswith psoriasis.METHODS: In a 12-week, double-blind, placebo-
controlled Phase 2b study, patients (n197) with moderate-to-severe plaque pso-
riasis were randomized to CP-690,550 (2, 5 or 15 mg BID) or placebo. Pruritus was
patient-assessed using the Itch Severity Score (ISS), a 0 (‘no itching’) to 10 (‘worst
possible itching’) numeric rating scale, recorded daily during the first 2 weeks of
treatment and at all clinic visits. The clinically important difference (CID) and
clinically important responder (CIR) on the ISS were defined using the Patient
Global Assessment as an anchor. RESULTS: At Baseline, mean (SD) ISS for patients
in the 2, 5, and 15mg BID and placebo groups were 7.04 (2.65), 6.98 (2.27), 6.96 (2.23),
and 6.78 (2.77), respectively. The estimated CID (95%CI) was 1.64 (1.50; 1.78) and CIR
was 29.8% (23.30%; 36.40%). Overall differences in ISS values between active drug
arms and placebowere2.82 (95%CI:3.71;1.92),3.02 (3.93;2.12), and3.87
(4.76; 2.98) for 2, 5, and 15 mg BID vs placebo, respectively; all differences were
larger (in absolute value) than the CID of 1.64, indicating that the treatment effects
were not only statistically significant but also clinically relevant. At Week 2, the
number of ISS responders was 77.78%, 68.75%, and 76.60% for 2, 5, and 15 mg BID,
respectively, vs 34.00% for placebo (p0.0001); at Week 12 the number of ISS re-
sponders increased to 91.89%, 87.18%, and 100% in the 2, 5, and 15 mg BID groups,
respectively, vs 29.41% for placebo (p0.0001). CONCLUSIONS: In patients with
psoriasis, CP-690,550 produces significant and clinically meaningful reductions in
pruritus, as measured by the patient-reported ISS.
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DISEASE SEVERITY EVALUATION AMONG DERMATOLOGICAL OUT-PATIENTS:
A COMPARISON BETWEEN THE ASSESSMENTS OF PATIENTS AND PHYSICIANS
Tabolli S, Sampogna F, Pagliarello C, Paradisi A, Spagnoli A, Abeni D
IDI IRCCS, Rome, Italy
OBJECTIVES: The assessment of a patient’s disease severity is an essential compo-
nent in the formulation of treatment strategies. This study wants to compare the
dermatological disease severity assessment by patients and by physicians, and to
describe the possible discrepancies between them.METHODS: For each patient, we
obtained the Physician Global Assessment (PhGA) and the Patient Global Assess-
ment (PtGA). Data were completed for 2.578 patients. Sixty-one physicians partic-
ipated in the study. We calculated the agreement between PtGA and PhGA scores
using the weighted kappa statistics; a multinomial logistic regression was per-
formed to assess the risk of disagreement considering both patient and physician
variables. RESULTS: Differences in the percentages of severity level, identified by
patients and by physicians, were always statistically significant (p0.05). Overall,
the weighted Cohen’s kappa was in the range of 0.09 - 0.34, depending on the
diseases. Gender differences betweenpatients andphysicians did not influence the
agreement. In the multinomial model female patients (OR1.38; 95%CI, 1.07-1.77),
patients with higher educational levels (OR2.71; 95%CI, 2.12-3.46), and patients
with impaired quality of life (OR1.56; 95%CI 1.23-1.97) had a higher risk to be
underestimated for their disease severity by physicians, independently by physi-
cian gender and experience. CONCLUSIONS: Combining the subjective report with
the objective severity assessment of the lesions, dermatologistsmay reach a better
determination of how severity of disease is perceived by their patients and how
they feel about the effectiveness of treatment. PtGA and PhGAmight be considered
in routine clinical assessments and not only for research activities.
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PSYCHOMETRIC EVALUATION OF THE NATIONAL EYE INSTITUTE VISUAL
FUNCTION QUESTIONNAIRE 25 AND VISUAL FUNCTION QUESTIONNAIRE
UTILITY INDEX IN PATIENTS WITH NON-INFECTIOUS INTERMEDIATE AND
POSTERIOR UVEITIS
Naik RK1, Gries KS2, Rentz A3, Kowalski JW1, Revicki DA3
1Allergan, Inc., Irvine, CA, USA, 2United BioSource Corporation, Seattle, WA, USA, 3United
BioSource Corporation, Bethesda, MD, USA
OBJECTIVES: To evaluate the psychometric properties of the National Eye Institute
Visual Function Questionnaire 25-item (NEI VFQ-25) and Visual Function Question-
naire Utilities Index (VFQ-UI) in patients with non-infectious intermediate and
posterior uveitis. METHODS: Secondary analysis of pooled data from a 26-week,
multicenter, masked, randomized, sham-controlled Phase 3 trial of dexametha-
sone intravitreal implant. Vision specific health related quality of life was assessed
using the NEI VFQ-25 at baseline and weeks 8, 16, and 26/early exit. The EQ-5D and
SF-36 were administered at baseline. Internal consistency reliability and reproduc-
ibility was measured using Cronbach’s alpha and intraclass correlation coefficient
(ICC). Validity was assessed with Spearman’s product-moment rank correlations
and known-groups of BCVA and vitreous haze severity. Clinically significant dif-
ferencewas assessed using distribution and anchor-basedmethods.RESULTS:The
study included 224 subjects with non-infectious intermediate (80.4%) or posterior
uveitis (19.6%); mean age 44.6 years; 63.4% female; 60.3% Caucasian; median vitre-
ous haze score at baseline 2.0 and median visual acuity (ETDRS) 62.5 letters (84.4%
treated in their worse seeing eye). The NEI VFQ-25 and the VFQ-UI demonstrated
good internal consistency (Cronbach’s alpha 0.87-0.94) and test-retest reliability
(ICC 0.72-0.88). Spearman’s product-moment rank correlations between the NEI
VFQ-25 andVFQ-UI scores and the SF-6D, EQ-5D, and BCVAat baseline ranged from
low to moderate. There was a significant association between visual functioning
and known groups of visual acuity, with group comparisons demonstrating signif-
icant decrease in visual functioning between 20/40 and 20/40 to 20/200
(p0.05). At week 8, clinically significant difference, based on the standard error of
measurement, was 0.04 for the VFQ-UI and ranged from 4.63 to 8.92 for the VFQ-25
domains and 3.86 for the composite score. CONCLUSIONS: The NEI VFQ-25 and the
VFQ-UI are reliable and valid measures of vision-related functioning and prefer-
ence-based status in patients with non-infectious intermediate and posterior uve-
itis.
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MEDIATION MODELING AND MEASUREMENT CHARACTERISTICS OF THE ITCH
SEVERITY SCORE FROM A PHASE 2B TRIAL OF ORAL CP-690-550 IN PATIENTS
WITH MODERATE TO-SEVERE PLAQUE PSORIASIS
Mamolo C1, Bushmakin AG2, Cappelleri JC2, Stewart M2
1Pfizer, New London, CT, USA, 2Pfizer Global Research and Development, Groton, CT, USA
OBJECTIVES: To assess direct and indirect effects of the oral Janus kinase inhibitor
CP-690,550 on pruritus in patients with psoriasis.METHODS: In a 12-week, double-
blind, placebo-controlled Phase 2b trial, 197 patients withmoderate-to-severe pso-
riasis were randomized to CP-690,550 (2, 5 or 15 mg BID) or placebo. Pruritus was
patient-assessed using the Itch Severity Score (ISS), a 0 (‘no itching’) to 10 (‘worst
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possible itching’) numeric rating scale, recorded daily during the first 2 weeks of
treatment and at clinic visits. Mediation modeling was used to determine the re-
lationship between ISS, the Physician’s Global Assessment (PGA, a clinicalmeasure
of psoriasis severity assessing erythema, induration, and scaling), and treatments
(2, 5, 15 mg BID vs placebo). Mediation modeling included ISS as the dependent
variable (averaged post-treatment ISS during weeks 2-12 for every patient), PGA as
the mediator variable (averaged post-treatment PGA score during weeks 2-12 for
every patient), and treatments (with each drug dose comparedwith placebo) as the
independent variables. Psychometric (correlational) analyses were performed on
ISS using post-baseline assessments. RESULTS: The direct effects of all CP-690,550
doses on ISS were 70%-81% (vs placebo; p0.001), indicating that drug effects on
pruritus were mostly independent of improvements in erythema, induration, and
scaling. Daily ISS measurements had acceptable test-retest reliability (intraclass
correlation: 0.83) in patients who did not change on PGA during the first 2 weeks of
the trial. Pearson correlations between ISS and other measures were consistent
with expectations; for example, weekly ISS correlated with weekly PGA (range:
0.30.5) and Patient Global Assessment (range: 0.60.7). CONCLUSIONS: In pa-
tients with psoriasis, CP-690,550 has a direct, beneficial effect on patient-reported
pruritus that is independent from improvements in clinician-reported psoriasis
severity. Post-baseline assessments of ISS showed favorable psychometric charac-
teristics, indicating its potential use as a simple tool for assessment of pruritus in
clinical trials.
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GAP ANALYSIS FOR PATIENT-REPORTED OUTCOMES MEASURES FOR ALOPECIA
Dennee-Sommers B1, Galipeau N1, Fitzgerald K1, Evans C1, Daniels S2, Burgess SM2
1MAPI Values, Boston, MA, USA, 2Allergan, Inc., Irvine, CA, USA
OBJECTIVES: To identify an existing patient-reported outcome (PRO) measure to
substantiate labeling or promotional claims for treatment in alopecia.METHODS:
MEDLINE®, PRO and Quality of Life Instruments (PROQOLID) and PRO and Drug
Marketing Authorizations (PROLabels) databases were searched and relevant in-
struments were identified by reviewing abstracts, articles, and labels for concepts
of interest (i.e., color/darkness, length, fullness/thickness, general appearance/
attractiveness, self-esteem). The initial instruments were further reviewed and
subsequently excluded if they were: not PROs (e.g., hair coverage), not specific to
scalp hair growth, or developed without patient input. The final list of instruments
was evaluated based on requirements outlined in the US Food and Drug Adminis-
tration’s Final PRO Guidance for Industry (e.g., development and confirmation of
conceptual framework, patient involvement in item generation, content validity,
recall period, response options, consideration of patient population used for devel-
opment in relation to future clinical trials). RESULTS: Forty-five instruments were
identified; 23were patient-reported, 17were investigator-rated, threewere devices
and two were objective hair measures. Forty-one were excluded based on the cri-
teria outlined. The four instruments considered further included alopecia-specific
items and instruments used to support the approval of drugs to stimulate hair
growth (e.g., Propecia®), specifically, the Kingsley Alopecia Questionnaire (KAP),
the Hair Growth Questionnaire, the Hair Problem List, and the Women’s Andro-
genic Alopecia Quality of Life Questionnaire (WAA-QOL). CONCLUSIONS: None of
the instruments met the PRO Guidance requirements; however, some could be
adapted. The Hair Growth Questionnaire could be revised and tested to confirm if
the content of the instrument is relevant for women with alopecia as it was devel-
oped based on male input only. Alternatively, the Hair Problem List or the WAA-
QOL could be supplemented to include more concepts of interest and tested to
confirm if the content of the instrument is relevant for both men and women with
alopecia.
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SYSTEMATIC REVIEW OF THE QUALITY OF LIFE LITERATURE IN CHILDREN
WITH ATOPIC DERMATITIS
Iskedjian M1, Navarro V2, Khondoker F1, Farah B3
1PharmIdeas Research and Consulting, Oakville, ON, Canada, 2PharmIdeas Europe SAS, Lyon,
France, 3PharmIdeas Research and Consulting, Ottawa, ON, Canada
OBJECTIVES: A systematic review of the literature was performed to elicit the
published evidence relating to quality of life (QOL) in children with atopic derma-
titis (AD).METHODS:OVIDMEDLINE® and EMBASE™were explored by two review-
ers for a combined search with terms related to economics and QOL in a paediatric
population, for the period 1996-2010. This abstract reports the results of the QOL
review. Two reviewers browsed abstracts, retrieved suitable articles and summa-
rized key findings. A third person acted as overall reviewer and adjudicator in case
of disagreement. RESULTS: From an initial search yielding 704 references, 51 pri-
mary research articles were included in the review, 14 reporting on QOL as primary
outcome and 37 as secondary outcome. QOL as a primary outcomewas reported for
Europe (n7), North America (n4), Asia (n3), Australia (n1) and South America
(n1). One study reported preference-based outcomes. Most studieswere based on
AD-specific tools such as the Children’s Dermatology Life Quality Index or the
Dermatology Life Quality Index (n6), the Infants’ Dermatitis Quality of Life Index
(n4), theQuality of Life Index for Atopic Dermatitis or the Parent’s Index of Quality
of Life–Atopic Dermatitis (n2) and the Dermatitis Family Impact Questionnaire
(n5). One studywas based on general QOLmeasures from the 12-itemShort-Form
Health Survey (SF-12). The studies targeting very young children most often used
parents as proxies.Most studies pointed to an inverse correlation betweenQOL and
severity as well as correlation between various instruments. Studies reporting on
QOL as a secondary outcome confirmed those findings. CONCLUSIONS: There is a
clear lack of studies eliciting health state utilities. Furthermore, most AD-specific
tools do not provide a standard, quantitative measurement in relation to perfect
health as would do preference based studies required for cost-utility analyses.
Further research should focus on utility measurement.
Sensory Systems Disorders – Health Care Use & Policy Studies
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COMPARING HEALTH-RISK BURDEN AND TOTAL HEALTHCARE COSTS OF
PSORIASIS WITH TOP FIVE CHRONIC CONDITIONS
Naim A1, Pitts J2, Chen CY3, Wright D3, Chalk MB2, Edington D3
1Centocor Ortho Biotech Services, LLC, Horsham, PA, USA, 2Chalk & Associates, Austin, TX,
USA, 3University of Michigan, Ann Arbor, MI, USA
OBJECTIVES: Psoriasis (PsO) is a chronic, episodic, immunological skin disease that
affects approximately 2-2.5% of US population. It may result in work productivity
loss and high overall healthcare costs for employers. However, the impact on
health-risks is not well studied. We compared health-risks, lost productivity, and
total direct healthcare costs among individuals with PsO and five most prevalent
chronic conditions. METHODS: Health-risk information and self-reported illness
days using health-risk assessment (HRA) data were examined and direct Health-
care costs (medical and pharmacy) using claims data for employees, retirees, and
their adult dependents of a large self-insured employer were compared from 2002-
2006 among individuals with RA and five most prevalent chronic conditions;
asthma, coronary artery disease/congestive heart failure (CAD/CHF), diabetes, hy-
pertension, chronic obstructive pulmonary disease (COPD). RESULTS: 54 individu-
als with PsOwere identified. The PsO cohort hadmoderate health-risk score (2.8/5)
which was comparable to individuals with asthma (2.8/5), CHF (2.9), hypertension
(2.6) and lower than diabetes (3.2/5) and COPD (3.4/5). A higher proportion (35.2%) of
individuals with PsO had 5 illness days per year as compared with individuals
with asthma (31.8%), CAD/CHF (25.9%), hypertension (20.4%), diabetes (28.4%), and
COPD (33%). Annual direct healthcare costs were also higher for individuals with
RA ($28,933) as compared to individuals with asthma ($25,814), CAD/CHF ($22,916),
hypertension ($18,632), and diabetes ($28,224), and lower as compared to individ-
uals with COPD ($38,839). CONCLUSIONS: Individuals with PsO have similar
health-risks but higher illness days, and direct healthcare costs as compared to the
individuals with five most prevalent chronic conditions. Psoriasis is a high costs
and lost productivity driver for employers. Population health based programs that
engage employees in appropriately managing their chronic conditions can help
employers reduce health-risks, improve productivity, andmay help reduce health-
care costs as well.
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MEDICATION CHOICE AND ASSOCIATED HEALTH CARE OUTCOMES AND
COSTS FOR PATIENTS WITH ACNE AND ACNE RELATED CONDITIONS IN THE
UNITED STATES
Patel P1, Lin HC2, Feldman SR3, Fleischer AB3, Nahata M4, Balkrishnan R2
1University of Georgia, Athens, GA, USA, 2University of Michigan, Ann Arbor, MI, USA, 3Wake
Forest University, Winston-Salem, NC, USA, 4Ohio State University, Columbus, OH, USA
OBJECTIVES: Acne is a common condition for which multiple treatment options
are available. The patterns of pharmacotherapy for acne and similar conditions,
and the effect of those patterns on cost, are not well characterized. This study
examined the impacts of patient demographics and medication choices on pa-
tient’s health status and associated medication costs. METHODS: A retrospective
cross-sectional study was conducted using the 2007 Medical Expenditure Panel
Survey (MEPS) database. Information onpatient demographics, health status,med-
ication utilization, and medication costs were obtained from the database repre-
senting 3,784,816 patients with acne and similar conditions. RESULTS: Weighted
multiple linear regression analyses indicated that the use of topical retinoids was
preferred in combination with other treatments rather than its monotherapy. Oral
antibiotics were widely prescribed and its use was associated with a significant
decrease in total annual prescription spending. Use of oral retinoids and oral con-
traceptives increased the annual prescription costs significantly. Increase in an-
nual drug refills was not associated with the improvement in health status.
CONCLUSIONS: We observed an association with medication choice for acne and
acne related conditions onmedication spending. Pharmacologic treatment of acne
significantly adds to acne related annual healthcare costs compared to non phar-
macologic treatment.
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MEDICATION ADHERENCE TO TOPICAL MEDICATIONS AND HEALTHCARE
EXPENDITURES IN MEDICAID-ENROLLED CHILD WITH ATOPIC DERMATITIS
Ou HT1, Feldman SR2, Balkrishnan R3
1University of Michigan College of Pharmacy, Ann Arbor, MI, USA, 2Wake Forest University,
Winston-Salem, NC, USA, 3University of Michigan, Ann Arbor, MI, USA
OBJECTIVES: To identify factors that predict adherence to topical medication in
pediatric population with atopic dermatitis (AD), and assess their impact on
healthcare expenditures. METHODS: AD patient’s age under 12 years old using
topic corticosteroid or topical calcineurin inhibitor (TCI) was identified using Mar-
ketScanTM Medicaid database from 2005 to 2007. Adherence to ADmedication and
costs for all healthcare claims and costs for AD related claims were outcomes of
interest and measured over 12 months when AD medication started. Medication
adherence was measured using medication possession ratio. Multiple regression
analysis was carried to examine predictors for medication adherence and their
predictions on healthcare costs. RESULTS: 4,182 patients were included, with a
mean age of 4 years. Adherence to ADmedication average was low (41%), with the
lowest rates in patients with low potency corticosteroid therapy alone including
alclometasone, desonide or hydrocortisone (39%) and the highest rates in those
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